PCPI is a leader in the development and maintenance of clinical performance measures. 

PCPI continues to focus on the development and maintenance of measures that support federal programs such as the Physician Quality Reporting System or the Electronic Health Record Incentive Program also known as Meaningful Use and as such continues to steward select measure(s) in the following clinical conditions or topic areas.

Please note: individual measures listed may not appear in numerical order as measures part of the original sets have been transitioned to medical specialty societies. 

Care Transitions

  • Measure #1: Reconciled Medication List Received by Discharged Patients
  • Measure #2: Timely Transition of Transition Record 
  • Measure #3: Transition Record with Specified Elements Received by Discharged Patients (Emergency Department Discharge)
  • ​Measure #4: Transition Record with Specified Elements Received by Discharged Patients (Inpatient Discharges)

Chronic Stable Coronary Artery Disease

  • Measure #7: Beta-Blocker Therapy – Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)

Dementia

  • Measure #2: Cognitive Assessment 

Eye Care I and II

  • Measure #1: Primary Open-Angle Glaucoma (POAG): Optic nerve evaluation
  • Measure #3: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures
  • Measure #4: Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
  • Measure #7: Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
  • Measure #8: Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care

Heart Failure

  • Measure #6: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
  • Measure #7: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensive Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction

Hepatitis C

  • Measure #8a: One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk
  • Measure #8b: Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users
  • Measure #8c: Referral to Treatment for Patients Identified with HCV Infection

Major Depressive Disorder – Adult

  • Measure #2: Adult Major Depressive Disorder (MDD): Suicide Risk Assessment

Major Depressive Disorder – Child and Adolescent

  • Measure #3: Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment

Oncology

  • Measure #2: Breast Cancer: Hormonal Therapy for Stage I (T1b)-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
  • Measure #3: Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients
  • Measure #8: Medical and Radiation - Pain Intensity Quantified

Preventive Care and Screening

  • Measure #1: Tobacco Use: Screening and Cessation Intervention
  • Measure #3: Unhealthy Alcohol Use: Screening & Brief Counseling
  • Measure #4: Influenza Immunization

Prostate Cancer

  • Measure #3: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients

In an effort to ensure PCPI’s continued leadership in the development of next generation measures and to more effectively support PCPI members in their measure development and maintenance efforts, PCPI restructured its measure development model in 2013, adopting a more de-centralized model for measure maintenance and providing PCPI members with the opportunity to directly manage the currency of performance measures relevant to their constituents.

As a result of these efforts, medical specialty societies have assumed responsibility for the ongoing maintenance of a large portion of measures in existing PCPI developed measure sets. View the list of PCPI-developed measures that are now stewarded and maintained externally by our partners in measure development. 

Before accessing or downloading any measures, please reference the Permission to Use Measures page, which includes Restrictions on Development of Derivative Works of PCPI Measures, as well as Continuing Medical Education Permissions and access to PCPI's Commercial Distribution License Application.